Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.
NCT03443362 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2022-07-19
Summary
Chronic urticaria (CU) is a disease that usually affects a large visible amount of surface of the skin. It is accompanied by severe itch and feeling of burned skin. Therefore the disease has a big impact on the quality of life of patients. Unfortunately, to date CU is not easily controlled by its few existing treatment options (i.e. antihistamines, omalizumab, cyclosporine).
This research's main perspective is to improve quality of life for CU patients by first of all focusing on a good clinical diagnosis of (different subtypes of) CU in a CU reference center, and secondly by gaining more insight on the pathogenesis of the disease to expand knowledge on potential new targeted treatments for the patients.
Conditions
- Chronic Urticaria
Interventions
- PROCEDURE
-
Punch Biopsy
A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
- PROCEDURE
-
Blood sampling
Blood sampling
Sponsors & Collaborators
-
Olivier Michel
lead OTHER
Principal Investigators
-
Yora Mostmans, MD · CHU Brugmann
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-01
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
Countries
- Belgium
Study Locations
More Related Trials
-
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)
NCT03111628 ·Status: COMPLETED ·Phase: PHASE4
-
Cold Urticaria Treatment With Xolair
NCT01580592 ·Status: COMPLETED ·Phase: PHASE2
-
T Cell Function in Chronic Idiopathic Urticaria
NCT01425593 ·Status: UNKNOWN
-
Effect of Anti-IgE in Chronic Urticaria
NCT00130234 ·Status: COMPLETED ·Phase: PHASE2
-
Urticaria Facticia Treatment With Omalizumab (UFO)
NCT02169115 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria
NCT01701583 ·Status: COMPLETED ·Phase: PHASE4
-
Dupilumab in Chronic Spontaneous Urticaria
NCT03749135 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
NCT01287117 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567 ·Status: COMPLETED ·Phase: PHASE2
-
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
NCT02550106 ·Status: COMPLETED ·Phase: PHASE4
-
Cholinergic Urticaria - Efficacy of Dupilumab
NCT03749148 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
NCT01713725 ·Status: COMPLETED ·Phase: PHASE2
-
Shotblocker® Use in Subcutaneous Injection
NCT04210323 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
NCT01292473 ·Status: COMPLETED ·Phase: PHASE3
-
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
NCT07166211 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
NCT01264939 ·Status: COMPLETED ·Phase: PHASE3
-
Real Life Use of Omalizumab in Chronic Urticaria
NCT04584190 ·Status: UNKNOWN
-
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
NCT02392624 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
NCT00866788 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
NCT03580356 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
NCT03437278 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
NCT02477332 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651 ·Status: RECRUITING ·Phase: PHASE2
-
Mepolizumab for the Treatment of Chronic Spontaneous Urticaria
NCT03494881 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy Study of Canakinumab to Treat Urticaria
NCT01635127 ·Status: UNKNOWN ·Phase: PHASE2